Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its outstanding common stock. The program has no time limit and can be discontinued at any time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
937.6 USD | +3.78% | +5.27% | +6.75% |
02/05 | Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177 | MT |
02/05 | Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.75% | 101B | |
-1.65% | 103B | |
+6.29% | 23.07B | |
-12.60% | 22.23B | |
-6.40% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B | |
+307.09% | 8.35B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc. announces an Equity Buyback for $3,000 million worth of its shares.